10 completed, 6 recruiting, 2 terminated, 1 not yet recruiting. 20 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 10, Recruiting 6, Terminated 2, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 6 | Completed 4, Terminated 2 |
Follow mogamulizumab: new trials by email Literature Review of mogamulizumab trials Research Report on mogamulizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of VG712 in Patients With Mycosis Fungoides VG712, Mogamulizumab - Mycosis Fungoides | Phase 2 | Not yet recruiting | Virogen Biotechnology Inc. | 386 | 2026-07-30 | 2026-04-14 |
| A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 Mogamulizumab - T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 134 | 2024-11-15 | 2026-03-05 |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol - T Cell Lymphoma, T-cell Lymphoma | Phase 2 | Recruiting | Yale University | 22 | 2024-10-09 | 2026-04-14 |
| Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas Pembrolizumab, Mogamulizumab - Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 23 | 2023-12-06 | 2026-05-05 |
| Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma Mogamulizumab, Total Skin Electron Beam Therapy (TSEB), Mogamulizumab (subsequent cycles post TSEB) - Stage IB-IIB Cutaneous T-Cell Lymphoma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 43 | 2023-03-07 | 2024-04-05 |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 34 | 2022-10-19 | 2026-09-02 |
| Mogamulizumab Q4week Dosing in Participants With R/R CTCL Mogamulizumab - Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory | Phase 2 | Unknown | Kyowa Kirin, Inc. | 34 | 2021-08-16 | 2024-04-25 |
| Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Emory University | 5 | 2021-04-21 | 2024-08-13 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome Mogamulizumab, LD TSEBT - Sezary Syndrome, Mycosis Fungoides | Phase 2 | Recruiting | Stanford University | 30 | 2020-03-30 | 2026-07-01 |
| Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Mogamulizumab, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2018-10-24 | 2023-09-21 |
| Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors Mogamulizumab + Nivolumab - Solid Tumor, Cancer | Phase 1 / Phase 2 | Completed | Kyowa Kirin, Inc. | 114 | 2016-02-01 | 2024-04-25 |
| Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Mogamulizumab (KW-0761) - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2014-10-01 | 2021-04-23 |
| KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) KW-0761, Pralatrexate, gemcitabine plus oxaliplatin - Adult T-cell Leukemia-Lymphoma | Phase 2 | Completed | Kyowa Kirin, Inc. | 71 | 2012-06-01 | 2024-04-25 |
| Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) KW-0761 (mogamulizumab) - Peripheral T-Cell Lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 38 | 2012-04-01 | 2024-06-17 |
| Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma KW-0761 - Peripheral T/NK-cell Lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 38 | 2010-09-01 | 2017-03-03 |
| Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 KW-0761 - Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 1 | 2010-08-01 | 2024-04-25 |
| Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 VCAP/AMP/VECP(mLSG15), KW-0761 - Adult T-cell Leukemia-Lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 44 | 2010-07-01 | 2017-03-30 |
| Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma KW-0761 - Adult T-cell Leukemia-lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 28 | 2009-06-01 | 2017-03-29 |
| Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma KW-0761 - Peripheral T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 42 | 2009-05-01 | 2024-04-25 |
Lymphoma, T-Cell, Cutaneous (7) · Mycosis Fungoides (5) · Sezary Syndrome (4) · Leukemia-Lymphoma, Adult T-Cell (3) · Lymphoma, T-Cell, Peripheral (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Lymphoma, T-Cell (2) · Neoplasms (2) · Recurrence (2) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Hematologic Neoplasms (1) · Leukemia, T-Cell (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1)
Kyowa Kirin Co., Ltd. (6) · Kyowa Kirin, Inc. (3) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · Emory University (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Stanford University (1) · University of Michigan Rogel Cancer Center (1) · Virogen Biotechnology Inc. (1) · Yale University (1)
United States (15) · France (4) · United Kingdom (4) · Italy (3) · Japan (3) · Spain (3) · Denmark (2) · Belgium (1) · Brazil (1) · Germany (1) · Greece (1) · Netherlands (1) · Peru (1)
Michael Kurman, MD (2) · Christiane R Querfeld (1) · Erel Joffe (1) · Jan Nicolay (1) · Jedd Wolchok, MD, PhD (1) · Michael Kurman, M.D. (1) · Michael S Khodadoust (1) · Pablo Luis Ortiz Romero (1) · Pamela B Allen (1) · Pier Luigi Zinzani, M.D., PhD (1) · Richard Cowan (1) · Ryan Wilcox (1) · Steven Horwitz, MD (1) · Tarsheen Sethi, MD (1) · Youn H Kim, MD (1)
PMID 22312108, PMID 24616310, PMID 25605368, PMID 25733162, PMID 27418646, PMID 41595202
P30CA033572 (1), P30CA138292 (1), UM1CA186691 (1), UM1CA186717 (1)